<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951232</url>
  </required_header>
  <id_info>
    <org_study_id>D2016058</org_study_id>
    <nct_id>NCT04951232</nct_id>
  </id_info>
  <brief_title>Clinical Study of Cinepazide Maleate Injection in the Treatment of Acute Ischemic Stroke</brief_title>
  <official_title>Cinepazide Maleate Injection in the Treatment of Acute Ischemic Stroke A Blind, Multicenter, Placebo-controlled Clinical Confirmatory Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel controlled,&#xD;
      post marketing confirmatory clinical trial in Chinese patients with acute ischemic stroke.&#xD;
      Objective to evaluate the efficacy and safety of cinepazide maleate injection compared with&#xD;
      placebo in the treatment of patients with acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The target population of this study is patients with acute ischemic stroke within 48 hours.&#xD;
      All potential participants must provide informed consent, and those who provide informed&#xD;
      consent will enter the screening (- 48 ~ 0h), and the screening qualification will be&#xD;
      evaluated according to the inclusion criteria. The eligible subjects will enter the treatment&#xD;
      period (day 1-14) and will be randomly assigned to the experimental group (cinepazide maleate&#xD;
      injection group) or the control group (placebo group).&#xD;
&#xD;
      During the treatment period, all subjects will receive cinepazide maleate injection or&#xD;
      placebo by intravenous drip at the rate of 100ml / h, once a day for 14 consecutive days.&#xD;
      During the treatment, all subjects need to receive basic treatment: citicoline sodium&#xD;
      injection 0.5g, dissolved in 5% glucose injection or normal saline 250ml, intravenous drip&#xD;
      slowly, once a day, continuous administration for 10 days. According to the Chinese&#xD;
      guidelines for the diagnosis and treatment of acute ischemic stroke (2014), the patients were&#xD;
      given antihypertensive, hypoglycemic, lipid-lowering, anticoagulant or mannitol. All subjects&#xD;
      were not allowed to receive interventional therapy, thrombolysis (such as rtPA and&#xD;
      urokinase), defibrillator, any platelet inhibitor except aspirin and clopidogrel, other&#xD;
      cerebrovascular dilators (such as cinnarizine, flunarizine, nicardipine and nimodipine),&#xD;
      other neuroprotective agents (except citicoline) during the whole trial period After the end&#xD;
      of the treatment period (the 14th day), the subjects will enter the follow-up period (the&#xD;
      15th-90th day).&#xD;
&#xD;
      During the follow-up period, subjects need to be followed up twice (30th day) ± 2 days, 90th&#xD;
      day ± 3 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2016</start_date>
  <completion_date type="Actual">January 6, 2017</completion_date>
  <primary_completion_date type="Actual">January 6, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>score of modified Rankin Scale(MRS)</measure>
    <time_frame>at day 90</time_frame>
    <description>proportion of subjects with a modified Rankin Scale (MRS) ≤ 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ability of daily life</measure>
    <time_frame>at day 90</time_frame>
    <description>the score of Barth index(BI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1000</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>Test group (cinnarizide maleate injection group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group (placebo group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cinepazide Maleate</intervention_name>
    <description>The experimental group: guipiprazitel maleate injection (klingo): 320mg (4), dissolved in 500ml of normal saline, and injected in a medium vein at a rate of 100ml/h, once a day, and administered for 14 days.</description>
    <arm_group_label>Test group (cinnarizide maleate injection group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 4 pieces, dissolved in normal saline 500ml, intravenous drip, the speed is 100ml / h, once a day, continuous administration for 14 days</description>
    <arm_group_label>control group (placebo group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. 18-80 years old (contains 18 and 80 years), with no limit for both sexes; 2. Acute&#xD;
             internal carotid artery was diagnosed according to the Chinese guidelines for the&#xD;
             diagnosis and treatment of acute ischemic stroke (2014) Cerebral infarction of the&#xD;
             arterial system (anterior circulation), well after first onset or last onset (MRS&#xD;
             score 0-1) patients; 3. Onset ≤ 48 hours (onset to randomization within 48 hours); 4.&#xD;
             5 points ≤ NIHSS ≤ 25 at presentation; 5. Informed consent was signed by the patients&#xD;
             or their legal surrogates.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients with recurrent cerebral infarction with pre Mrs score ≥ 2 at this time; 2.&#xD;
             Cranial CT suggestive of intracranial haemorrhagic disease (e.g Intracranial hematoma,&#xD;
             intraventricular hemorrhage, subarachnoid hemorrhage, etc.); 3. Cerebral infarction&#xD;
             with impaired consciousness (NIHSS score of 1A items ≥ 1), transient ischemic attack&#xD;
             Zuo, cerebral arteritis, brain tumor, brain trauma, intracranial infection, cerebral&#xD;
             parasite disease patients; 4. Patients who have undergone or require interventional,&#xD;
             thrombolytic, and defibrillation therapy after this episode; 5. History or evidence of&#xD;
             any one of the following diseases during the screening period:&#xD;
&#xD;
               -  poorly controlled hypertension with systolic blood pressure ≥ 200mmhg or&#xD;
                  diastolic blood pressure ≥ 110mmhg during screening period;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongsheng Fan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cinepazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

